| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$46,284 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
51,160 |
55,427 |
107,411 |
368,796 |
| Total Sell Value |
$607,960 |
$642,534 |
$943,036 |
$2,119,530 |
| Total People Sold |
1 |
2 |
4 |
10 |
| Total Sell Transactions |
1 |
2 |
5 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hussain Iqbal J |
General Counsel |
• – – |
2023-12-31 |
4 |
D |
$7.96 |
$59,859 |
D/D |
(7,520) |
185,435 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2023-12-31 |
4 |
D |
$7.96 |
$82,935 |
D/D |
(10,419) |
255,374 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2023-12-31 |
4 |
D |
$7.96 |
$93,466 |
D/D |
(11,742) |
257,097 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2023-09-30 |
4 |
D |
$6.47 |
$48,654 |
D/D |
(7,520) |
192,955 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2023-09-30 |
4 |
D |
$6.47 |
$30,409 |
D/D |
(4,700) |
967,490 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2023-09-30 |
4 |
D |
$6.47 |
$67,411 |
D/D |
(10,419) |
265,793 |
|
- |
|
| Saha Saurabh |
Chief Executive Officer |
• • – |
2023-09-30 |
4 |
D |
$6.47 |
$234,622 |
D/D |
(36,263) |
822,836 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2023-09-30 |
4 |
D |
$6.47 |
$41,531 |
D/D |
(6,419) |
144,264 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2023-09-30 |
4 |
D |
$6.47 |
$75,971 |
D/D |
(11,742) |
268,839 |
|
- |
|
| Rotman Harris |
SVP Regulatory Affairs |
• – – |
2023-09-20 |
4 |
AS |
$6.29 |
$235,688 |
D/D |
(37,484) |
33,500 |
|
- |
|
| Rotman Harris |
SVP Regulatory Affairs |
• – – |
2023-09-20 |
4 |
OE |
$3.85 |
$163,688 |
D/D |
37,484 |
70,984 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2023-06-30 |
4 |
D |
$5.90 |
$61,473 |
D/D |
(10,419) |
276,212 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2023-06-30 |
4 |
D |
$5.90 |
$25,311 |
D/D |
(4,290) |
972,190 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
D |
$5.90 |
$69,279 |
D/D |
(11,742) |
280,581 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2023-06-30 |
4 |
D |
$5.90 |
$41,914 |
D/D |
(7,104) |
200,475 |
|
- |
|
| Saha Saurabh |
Chief Executive Officer |
• • – |
2023-06-30 |
4 |
D |
$5.90 |
$213,955 |
D/D |
(36,263) |
859,099 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2023-06-30 |
4 |
D |
$5.90 |
$37,873 |
D/D |
(6,419) |
150,683 |
|
- |
|
| Rotman Harris |
SVP Regulatory AffairsOfficer |
• – – |
2023-06-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,500 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-06-01 |
4 |
AS |
$4.45 |
$28,949 |
D/D |
(6,500) |
783,066 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2023-05-24 |
4 |
S |
$4.48 |
$35,865 |
I/I |
(8,000) |
0 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-05-01 |
4 |
AS |
$4.42 |
$30,083 |
D/D |
(6,800) |
789,566 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-03-01 |
4 |
AS |
$3.42 |
$23,970 |
D/D |
(7,000) |
806,681 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-02-01 |
4 |
AS |
$3.79 |
$29,201 |
D/D |
(7,700) |
813,681 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,200 |
821,381 |
|
- |
|
| Saha Saurabh |
Chief Executive Officer |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
211,400 |
917,375 |
|
- |
|
147 Records found
|
|
Page 2 of 6 |
|
|
